

December 28, 2018

Listed Company Name: Sumitomo Dainippon Pharma Co., Ltd.  
Representative: Hiroshi Nomura,  
Representative Director  
President and CEO  
Headquarters: 6-8, Doshomachi 2-Chome,  
Chuo-ku, Osaka  
Securities Code: 4506  
Listed Locations: First Section of the  
Tokyo Stock Exchange  
Inquiries: Atsuko Higuchi  
Executive Officer  
Executive Communication Officer  
TEL: +81-6-6203-1407(Osaka)  
+81-3-5159-3300(Tokyo)

**Correction to “Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA® in the U.S.”**

Sumitomo Dainippon Pharma Co., Ltd. announces the following correction to “Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA® in the U.S.” disclosed on November 27, 2018. Corrected part is underlined.

(Before Correction)

(Pursuant to the Settlements and other settlement agreements entered with some of the defendants of this Lawsuit, certain number of generic companies that were parties to the Lawsuit will be permitted to distribute their generic versions of lurasidone HCL starting on February 21, 2023.)

(After Correction)

(Pursuant to the Settlements and other settlement agreements entered with some of the defendants of this Lawsuit, certain number of generic companies that were parties to the Lawsuit will be permitted to distribute their generic versions of lurasidone HCL starting on February 20, 2023.)